Severe Pulmonary Disease Associated with Electronic-Cigarette–Product Use — Interim Guidance

• DOI: 10.15585/mmwr.mm6836e2
• Publication Date: 2019-09-06T17:15:53Z
• Authors: Joshua G. Schier; Jonathan G. Meiman; Jennifer Layden; Christina A. Mikosz; Brenna VanFrank; Brian A King; Phillip P. Salvatore; David N. Weissman; Jerry Thomas; Paul C. Melstrom; Grant T. Baldwin; Erin M. Parker; Elizabeth A. Cour...; Vikram P. Krishna...; Cassandra M. Pickens; Mary E. Evans; Sharon V. Tsay; Krista M. Powell; Emily A. Kiernan; Kristy L. Marynak; Jennifer Adjemian; Kelly Holton; Brian S. Armour; Lucinda J. England; Peter A. Briss; Debra Houry; Karen A. Hacker; Sarah Reagan-Steiner; Sherif Zaki; Dana Meaney-Delman
• Keywords: Electronic cigarette; Nebulizer; Interim

On September 6, 2019, this report was posted as an MMWR Early Release on the website (https://www.cdc.gov/mmwr). As of August 27, 215 possible cases severe pulmonary disease associated with use electronic cigarette (e-cigarette) products (e.g., devices, liquids, refill pods, and cartridges) had been reported to CDC by 25 state health departments. E-cigarettes are devices that produce aerosol heating a liquid containing various chemicals, including nicotine, flavorings, other additives propellants, solvents, oils). Users inhale aerosol, any additives, into their lungs. Aerosols produced e-cigarettes can contain harmful or potentially substances, heavy metals such lead, volatile organic compounds, ultrafine particles, cancer-causing agents chemicals used for cleaning device (1). also be deliver tetrahydrocannabinol (THC), principal psychoactive component cannabis, drugs; example, "dabbing" involves superheating substances high concentrations THC plant compounds cannabidiol) intent inhaling aerosol. E-cigarette users could add devices. This summarizes available information provides interim case definitions guidance reporting disease. The in reflects data 2019; will updated additional becomes available.